Extended local release of anti-CSFR1 antibodies
The present disclosure provides compositions and methods for extended release of certain types of antibodies in vivo. It was discovered that such antibodies are able to initiate reversible gelation of hyaluronic acid (HA) by creating a depot that dissociates over time to release the antibody without any impact on its physical and chemical properties as well as its biological activity. As certain tissues and organs, such as eyes, joints and skins, contain HA, local injection of the antibodies to these tissues or organs will result in embedding of the antibody in gel formed from the HA, which becomes a repository of slow-released antibodies. In addition, slow-released formulations can be prepared with antibodies mixed with HA, optionally with other polymers.
1. A method for providing extended release of an antibody in a mammalian subject in need thereof, comprising injection of an aqueous solution comprising at least 15 mg/mL of the antibody to or near a tissue in the mammalian subject,
wherein the antibody is AM001, and the solution has a pH between 4.5 and 5.5,
wherein AM001 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:7 and a light chain comprising the amino acid sequence of SEQ ID NO:8,
wherein the aqueous solution includes less than 100 mM of an alkaline salt or a salt of an amino acid,
wherein the tissue contains hyaluronic acid (HA),
wherein the antibody reversibly forms gel with HA.
2. A method for providing extended release of an antibody in a mammalian subject in need thereof, comprising injection of an aqueous solution comprising at least 15 mg/mL of the antibody to or near a tissue in the mammalian subject,
wherein the antibody is Emactuzumab, and the solution has a pH between 5.5 and 6.5,
wherein the aqueous solution includes less than 100 mM of an alkaline salt or a salt of an amino acid,
wherein the tissue contains hyaluronic acid (HA),
wherein the antibody reversibly forms gel with HA.
3. The method of claim 1 , wherein the tissue is a joint.
4. The method of claim 1 , wherein the solution further comprises HA.
5. The method of claim 2 , wherein the tissue is a joint.